nAMD and DME Management: Game-Changing Sustained Delivery Platforms
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Activity Description
The frequent treatment and monitoring necessary to maintain visual and anatomical outcomes of patients with retinal vascular diseases receiving intravitreal anti-vascular endothelial growth factor therapies can be challenging to sustain. The number of clinical visits results in a considerable burden for patients and caregivers, often leading to undertreatment due to loss of adherence. To address this unmet need, gene therapies and novel delivery systems that reduce treatment frequency have been developed and assessed in clinical and real-world studies. These novel treatments offer the potential to revolutionize the treatment paradigm for patients with retinal vascular diseases. This CE activity utilizes Curbside Consults, a dynamic and interactive case-based platform that will highlight how the utilization of sustained delivery systems can improve visual outcomes and adherence in patients with neovascular age-related macular degeneration and diabetic macular edema. Experts in the field will also evaluate the latest clinical and real-world data, along with practices and procedures that can improve current and future use of sustained delivery systems in the management of patients with retinal diseases.
Target Audience
The intended audience for this activity is ophthalmologists involved in the management of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Summarize how sustained delivery systems, including gene therapy, can improve visual outcomes and adherence in patients with nAMD and DME.
- Interpret the latest clinical findings regarding the use of sustained delivery systems in the treatment of patients with nAMD and DME.
- Incorporate practices and procedures that can improve the current and future use of sustained delivery systems in the management of nAMD and DME.
Activity Chair
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Professor of Surgery
University of Nevada, Reno School of Medicine
Reno, NV
Faculty
Sara J. Haug, MD, PhD
Managing Partner, Southwest Eye Consultants
Owner, Southwest Retina Research Center
Durango, CO
Dante J. Pieramici, MD
Director, California Retina Research Foundation
Partner, California Retina Consultants
Santa Barbara, CA
Lejla Vajzovic, MD, FASRS
Director, Duke Surgical Vitreoretinal Fellowship Program
Co-Director, Duke Pediatric Retina and Optic Nerve Center
Director, Duke Eye Center Continuing Medical Education
Professor of Ophthalmology With Tenure
Adult and Pediatric Vitreoretinal Surgery and Diseases
Duke University Eye Center
Durham, NC
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, November 29, 2024, to November 28, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Sara J. Haug, MD, PhD
Consultant: Genentech, Roche
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, AbbVie, Adverum, Alcon, Amgen, Annexin, Annexon, Apellis, Aviceda, Beacon, Boehringer Ingelheim, Clearside, Complement Therapeutics, Exegenesis, EyePoint, Frontera, Genentech, Gyroscope, i-Lumen, IVERIC bio, Janssen, Kodiak, Kriya, Kyowa Kirin, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olive BioPharma, Opthea, Oxular, Oxurion, Perfuse, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, Revive, RevOpsis, Roche, Sanofi, Stealth BioTherapeutics, Thea, Unity Bio, Vanotech, Vial
Independent Research Contractor: 4DMT, Adverum, Alexion, Annexon, Apellis, Aviceda, Eluminex, EyePoint, Exegenesis, Genentech, Gyroscope, IVERIC bio, Janssen, Kodiak, Kyowa Kirin, Neurotech, Ocular Therapeutix, Oxular, Regenxbio
Stock Options: Aviceda, Oculis, Opthea, Perfuse, PolyPhotonix, RecensMedical, RevOpsis, Vial
*Individual Stocks (privately held): RevOpsis
Dante J. Pieramici, MD
Consultant: Adverum, EyePoint, Genentech, Neurotech, Perceiv, Regeneron, Regenxbio, SMIR, Stealth, Unity
Independent Research Contractor: 4DMT, Adverum, Apellis, Aviceda, EyeBio, EyePoint, Genentech, Janssen, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Regeneron, Regenxbio, Unity, Valo
Lejla Vajzovic, MD, FASRS
Advisor: Astellas, BioCryst, Clearside, Ocugen, Ocular Therapeutix, Regenxbio
Consultant: AbbVie/Allergan, Alcon, Alimera, Apellis, Bausch + Lomb, BVI, BMC, Clearside, Coherus, DORC, Genentech, Guidepoint, Gyroscope, IVERIC bio, Janssen/J&J Vision, Lexitas, Nanoscope, Novartis, Ocugen, Ocular Therapeutix, Ocular Surgical, OcuTerra, ONL Therapeutics, Outlook Therapeutics, Regeneron, Regenxbio
Speaker Contracted by Ineligible Company: AbbVie/Allergan, Alcon, Apellis, DORC, IVERIC bio, Ocular Surgical
Independent Research Contractor: AGTC, Alcon, Aldeyra, Apellis, Genentech, Gyroscope, Heidelberg Engineering, Janssen/J&J Vision, Novartis, Ocular Therapeutix, Regenxbio
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com